Crossmark

COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2024.100473

Published Print: 2024-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Li, Pengyang http://orcid.org/0000-0003-2272-9102
Chen, Qun http://orcid.org/0000-0001-5683-7844
Jovin, Ion S. http://orcid.org/0000-0002-4187-2919
Mankad, Anit

Huizar, Jose F. http://orcid.org/0000-0002-5073-9765
Markley, John D. http://orcid.org/0009-0002-7644-9720
Bart, Bradley http://orcid.org/0000-0002-0949-4567
Hattler, Brack http://orcid.org/0000-0002-4061-9129
Lesnefsky, Edward http://orcid.org/0000-0002-9672-7065
McFalls, Edward O. http://orcid.org/0000-0002-3933-6666
License Information

Text and Data Mining valid from 2024-01-01

Text and Data Mining valid from 2024-01-01

Version of Record valid from 2024-07-25
More Information

This article is maintained by: Elsevier

Article Title: COVID-19 and myocardial injury: Targeting elevated biomarkers for potential novel therapies

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2024.100473

Content Type: article

Copyright: © 2024 HCFMUSP. Published by Elsevier España, S.L.U.